US Patent 11,779,554: Solriamfetol Breastfeeding Claims, Scope, Expiration and Patent Landscape
US Patent 11,779,554 protects a narrow lactation-management method for solriamfetol, the active ingredient in Sunosi. Its core requirements are a once-daily maternal dose of either 150 mg or 75 mg, breastfeeding at least about five hours after dosing, and reduction of the infant’s daily solriamfetol exposure to about 0.3 mg or 0.15 mg, respectively. The patent does not broadly claim solriamfetol, Sunosi, treatment of narcolepsy, or treatment of obstructive sleep apnea.
The patent is commercially important as a potential lifecycle-management right, but its practical enforcement value is narrower than a conventional composition, formulation, or approved method-of-use patent.
What does US Patent 11,779,554 protect?
The independent claims protect two dose-and-timing regimens:
| Independent claim |
Maternal dose |
Breastfeeding timing |
Infant exposure limit |
Claimed objective |
| Claim 1 |
About 150 mg once daily |
At least about 5 hours after dosing |
About 0.3 mg/day or lower |
Reduce risk of infant agitation |
| Claim 10 |
About 75 mg once daily |
At least about 5 hours after dosing |
About 0.15 mg/day or lower |
Reduce risk of infant agitation |
The claims require all elements to be satisfied. A product or clinical practice that omits one material element, such as the five-hour interval or the specified maternal dose, would fall outside the literal scope of the independent claims.
The patent is therefore a patient-management patent, not a product patent. It covers conduct involving:
- A human subject treated orally with solriamfetol.
- A once-daily maternal dose of approximately 150 mg or 75 mg.
- Breast milk collection or feeding at least approximately five hours after administration.
- An infant daily exposure at or below the specified threshold.
- A stated objective of reducing agitation risk.
How do claims 1 through 18 divide the patent scope?
Claims 1 and 10 contain the principal commercial scope. The remaining claims add patient characteristics, treatment indications, or outcome limitations.
Claims 2 and 11: no observed agitation
Claims 2 and 11 require that the infant does not experience agitation due to solriamfetol exposure. These claims are narrower than claims 1 and 10 and may be difficult to prove prospectively because they depend on an observed clinical outcome.
They may have value in clinical protocols or retrospective infringement theories, but they add evidentiary complexity. A claimant would need to establish both solriamfetol exposure and the causal relationship between exposure and the absence or presence of agitation.
Claims 3, 4, 12 and 13: postpartum periods
The claims cover two overlapping postpartum ranges:
| Claims |
Postpartum range |
| 3 and 12 |
1 day to 24 months postpartum |
| 4 and 13 |
11 days to 12 months postpartum |
Claims 4 and 13 are narrower than claims 3 and 12. The ranges appear directed to lactating patients at different stages after delivery, potentially reflecting pharmacokinetic or milk-transfer data.
Claims 5 through 8 and 14 through 17: treatment indications
These claims extend the method to a long list of conditions and therapeutic objectives, including:
- Excessive daytime sleepiness
- Narcolepsy
- Obstructive sleep apnea
- Shift work disorder
- Attention deficit hyperactivity disorder
- Binge eating disorder
- Depression
- Parkinson’s disease
- Cognitive impairment
- Improvement of wakefulness
Claims 6, 7, 15 and 16 narrow the broader indication groups. Claims 8 and 17 focus on improving wakefulness rather than a particular diagnosis.
These dependent claims do not expand the patent beyond the lactation regimen. They create alternative infringement pathways if the maternal treatment is documented for one of the listed conditions.
Claims 9 and 18: patient demographics
Claims 9 and 18 require that the subject be a woman aged 18 to 50 years. These limitations align with the likely target population for reproductive and lactation use but materially narrow the claims.
What is the claim construction risk for US 11,779,554?
The principal claim terms likely to drive validity and infringement disputes are “about,” “at least about 5 hours,” “daily infant dose,” “reduced,” “risk of agitation,” and “due to solriamfetol exposure.”
“About” dose limitations
The claims do not state an exact numerical tolerance for “about 150 mg,” “about 75 mg,” “about 0.3 mg,” or “about 0.15 mg.” Claim scope will depend on the specification, prosecution history, technical context, and accepted dosing practice.
A patient receiving a marketed 150 mg or 75 mg tablet is more likely to fall within the maternal-dose limitations than a patient receiving an unconventional dose. The infant-dose limitation creates a separate question: whether the claimed infant dose means estimated systemic ingestion through milk, calculated oral intake, or another pharmacokinetic measure.
Five-hour timing limitation
The five-hour interval is a central narrowing element. Breastfeeding before five hours, where documented, would create a potential noninfringement position. The phrase “at least about 5 hours” may cover a period somewhat shorter than five hours, but the applicable tolerance would require evidence from the patent record.
“Reduced” infant dose
The claim language describes reduction to a numerical level but does not, on its face, require a comparison against a specific baseline. A dispute could arise over whether the reduction is measured against maternal dose, unrestricted breastfeeding exposure, a modeled exposure level, or another reference point.
Risk reduction and agitation
The claims are directed to reducing the risk of agitation, not merely reducing milk concentration. The patent’s practical value will depend on whether the claimed pharmacokinetic threshold is adequately linked to that clinical outcome in the specification and prosecution record.
What are the likely infringement theories?
Direct infringement would require performance of every claimed method step. Potential actors include:
- A lactating patient taking solriamfetol.
- A physician prescribing a dose and timing regimen.
- A healthcare provider instructing the patient when to breastfeed.
- A clinical study sponsor implementing the regimen.
- A caregiver feeding the infant after the specified interval.
The multiactor structure creates enforcement risk. The claims require maternal administration and infant feeding, which may be performed by different people. A patent owner could pursue induced or contributory infringement against a manufacturer or healthcare provider if evidence shows that the accused party knowingly encouraged performance of the complete method.
A generic applicant that merely seeks approval to market solriamfetol would not automatically infringe these claims. Exposure would increase if the proposed labeling, patient instructions, medication guide, or risk-management materials specifically instruct breastfeeding patients to use the claimed dose-and-five-hour regimen.
What is the FDA and Orange Book status of solriamfetol?
Solriamfetol is marketed in the United States as Sunosi by Jazz Pharmaceuticals. The FDA approved Sunosi in 2019 for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The approved dosage range includes 37.5 mg, 75 mg and 150 mg once daily, subject to the product labeling.[1]
The FDA-approved indication does not establish approval for:
- Shift work disorder
- Attention deficit hyperactivity disorder
- Binge eating disorder
- Depression
- Parkinson’s disease
- General cognitive impairment
- Lactation-related infant agitation-risk reduction
This distinction matters under the Hatch-Waxman framework. Method-of-use patents generally receive Orange Book listing treatment when they claim an approved method of using the drug and are submitted in accordance with FDA listing requirements. A lactation-management patent directed to a non-approved use may have limited Orange Book relevance even if it is technically related to an approved product.
The patent’s exact Orange Book listing status should be assessed against current FDA Orange Book data and the product sponsor’s submitted patent declarations. The claim language alone does not establish that US 11,779,554 is listed for Sunosi.
When does US Patent 11,779,554 lose exclusivity?
The patent issued on October 3, 2023. Patent expiration cannot be determined accurately from the issued claims alone because the controlling date depends on the earliest effective nonprovisional priority filing, any patent-term adjustment, terminal disclaimer, patent-term extension, and relevant prosecution history.
For a pharmaceutical method patent, the ordinary framework is a 20-year term measured from the earliest effective nonprovisional filing date, subject to statutory adjustments.[2] The issue date is not the expiration date.
The patent’s commercial exclusivity should therefore be analyzed through the following timeline:
| Event |
Date or status |
| Patent issuance |
October 3, 2023 |
| Ordinary term basis |
20 years from applicable earliest nonprovisional filing date |
| Patent-term adjustment |
Must be confirmed from the issued patent record |
| Terminal disclaimer |
Must be checked against related Jazz or solriamfetol patents |
| Patent-term extension |
No conclusion follows from the claims alone |
| Small-molecule generic entry |
Potentially affected only if the patent is listed and relevant to an ANDA certification |
What Paragraph IV risks exist for generic solriamfetol?
A generic applicant seeking approval for solriamfetol may face Paragraph IV issues if US 11,779,554 is listed in the Orange Book and the applicant’s proposed labeling or instructions read on the claims.
The risk is lower where the ANDA applicant:
- Omits the lactation regimen from labeling through a permissible section viii carve-out.
- Does not promote the five-hour breastfeeding interval.
- Uses labeling limited to FDA-approved narcolepsy and obstructive sleep apnea indications.
- Does not provide instructions that reduce infant exposure to the claimed numerical thresholds.
A Paragraph IV challenge could argue that the claims are invalid or not infringed. Potential validity theories include lack of novelty, obviousness based on solriamfetol pharmacokinetics and lactation data, lack of written description, enablement, indefiniteness, and improper functional claiming.
The method’s numerical thresholds and five-hour interval may provide patentability arguments if the specification demonstrates an unexpected reduction in infant exposure or agitation risk. The same limitations can make infringement proof more difficult.
Does US 11,779,554 create biosimilar risk?
No. Solriamfetol is a small-molecule drug, so a competing product would ordinarily proceed through the abbreviated new drug application pathway rather than the biosimilar pathway under the Public Health Service Act.
The relevant competitive threat is generic solriamfetol, not a biosimilar. The patent may delay or constrain a generic’s labeling only if the patent is listed, remains enforceable, and covers information that the generic cannot lawfully omit.
What formulations and manufacturing rights protect solriamfetol?
US 11,779,554 does not claim:
- Solriamfetol free base or a salt as a chemical entity.
- Tablet composition.
- Excipients.
- Immediate-release formulation technology.
- Controlled-release delivery.
- Crystal form or polymorph.
- Manufacturing process.
- Synthetic intermediate.
- Packaging or device.
Those rights, if active, would reside in separate solriamfetol patent families. They may create earlier or later barriers to generic entry than the lactation patent. A complete freedom-to-operate analysis must separate:
- Active-ingredient patents.
- Formulation and dosage-form patents.
- Manufacturing patents.
- Approved method-of-use patents.
- Lactation and patient-management patents.
The claims provided for US 11,779,554 establish only the fifth category.
How strong is the patent estate for this lactation use?
The estate appears narrow but potentially differentiated.
| Factor |
Assessment |
| Chemical composition coverage |
None in the supplied claims |
| Formulation coverage |
None |
| Manufacturing coverage |
None |
| Lactation-specific coverage |
Direct and substantial |
| Dose specificity |
Strong narrowing feature |
| Timing specificity |
Strong narrowing feature |
| Clinical-outcome language |
Potential evidentiary weakness |
| Generic labeling relevance |
Depends heavily on Orange Book listing and label content |
| Biosimilar exposure |
Not applicable |
| Enforcement complexity |
Elevated because multiple actors perform the method |
The strongest commercial position is against a branded or generic product accompanied by explicit instructions to administer 75 mg or 150 mg once daily and breastfeed after approximately five hours. The weakest position is against a generic label that omits lactation instructions and does not encourage the claimed conduct.
What patent litigation or settlement agreements affect this patent?
The supplied claim text does not establish any infringement action, Paragraph IV litigation, settlement agreement, license, or covenant not to sue involving US 11,779,554. No litigation or settlement conclusion should be inferred solely from issuance of the patent.
Any litigation assessment must distinguish this patent from earlier solriamfetol composition, formulation and approved-use patents. A settlement involving another Jazz solriamfetol patent would not necessarily resolve rights under US 11,779,554 unless the agreement expressly covers the patent or its patent family.
Key Takeaways
- US 11,779,554 is a narrow method patent directed to breastfeeding management after maternal solriamfetol dosing.
- Claims 1 and 10 are the commercial center of gravity, covering 150 mg and 75 mg once-daily regimens.
- The five-hour breastfeeding interval and infant exposure thresholds are mandatory claim elements.
- The patent does not claim solriamfetol, Sunosi, a formulation, or a manufacturing process.
- The approved FDA indications for Sunosi are narcolepsy- and obstructive-sleep-apnea-related excessive daytime sleepiness, not lactation management.
- Generic risk depends on Orange Book listing, proposed labeling, and whether the generic encourages the claimed breastfeeding regimen.
- Biosimilar analysis is irrelevant because solriamfetol is a small molecule.
- The patent’s multiactor method structure and outcome-based limitations create enforcement and proof issues.
- The exact expiration date requires the patent’s priority, patent-term-adjustment and terminal-disclaimer records.
FAQs
Can a generic sell solriamfetol without infringing US 11,779,554?
Yes, potentially. A generic may avoid infringement if its labeling does not instruct or encourage the claimed maternal dose, five-hour breastfeeding interval, and infant-exposure limitation. The answer also depends on whether the patent is listed and how the generic addresses it in its ANDA.
Does taking Sunosi while breastfeeding automatically infringe the patent?
No. The claims require a specific dose, timing interval, infant-exposure threshold, and claimed risk-reduction method. Breastfeeding while taking solriamfetol alone does not satisfy every limitation.
Are the 75 mg and 150 mg claims independent patent rights?
Yes. Claims 1 and 10 are separate independent claims directed to different maternal dose and infant-exposure thresholds. A practice outside one regimen could still fall within the other if all of its limitations are met.
Can a physician be liable for recommending the five-hour breastfeeding interval?
Potentially, depending on the physician’s conduct, knowledge, intent, and role in causing performance of the complete claimed method. Direct infringement and induced infringement require different factual showings.
Does the patent prevent approval of a solriamfetol generic for narcolepsy?
Not necessarily. A generic may be able to seek approval for approved indications while omitting a patented lactation-related use, subject to applicable FDA labeling and patent-certification rules.
References
- U.S. Food and Drug Administration. (2019). Sunosi (solriamfetol) prescribing information.
- 35 U.S.C. §§ 154, 156, 271, 355.
- U.S. Patent No. 11,779,554. (2023). Methods of reducing the risk of agitation in an infant exposed to solriamfetol through breast milk. United States Patent and Trademark Office.
